Good Morning! Latin America: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Good Morning! Latin America.

Press releases published on October 14, 2026

4 hours ago

Tempest Appoints John W. Frederick to Board of Directors, Strengthening Financial and Capital Markets Expertise

Indeterminate GlobeNewswire

4 hours ago

CAMP4 to Participate in Chardan’s 10th Annual Healthcare Conference

Indeterminate GlobeNewswire

5 hours ago

One Bullion Receives Final Maitengwe Airborne Geophysical Dataset and Provides Vumba Drilling Update

Indeterminate GlobeNewswire

5 hours ago

NIOB Airborne Survey Identifies Rare Earth Targets at Bardy SE

Indeterminate GlobeNewswire

5 hours ago

Invivyd and the SPEAR Study Group Announce Initiation of “FLINTLOCK” Phase 2 Study of VYD2311, a Monoclonal Antibody for the Potential Treatment of Long COVID or Post-Vaccination Syndrome

Indeterminate GlobeNewswire

5 hours ago

Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Top Dose of 18 mg/kg in Entrada Therapeutics’ ELEVATE-44-201 Study

Indeterminate GlobeNewswire

5 hours ago

Entrada Therapeutics Announces Positive Results from the First Cohort of Participants with Duchenne Muscular Dystrophy (DMD) in the Phase 1/2 ELEVATE-45-201 Study of ENTR-601-45

Indeterminate GlobeNewswire

5 hours ago

Arexera Therapeutics, Formerly Atalanta Therapeutics, Unveils New Corporate Identity and Advances Huntington's Disease Franchise

Indeterminate GlobeNewswire

5 hours ago

Elion Therapeutics Expands Pipeline with Exclusive Global License to Inhaled Antifungal for Immunocompromised Patients

Indeterminate GlobeNewswire

5 hours ago

Parabilis Medicines Initiates Dose-Ranging Clinical Study of Zolucatetide in Familial Adenomatous Polyposis

Indeterminate GlobeNewswire

5 hours ago

Aya Gold & Silver Reports Record Q3-2026 Production of 2.03 Million AgEq Ounces

Indeterminate GlobeNewswire

6 hours ago

Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Peeling Skin Syndrome

Indeterminate GlobeNewswire

7 hours ago

Rakovina Therapeutics Secures Exclusivity on Optimized kt-5000 Lead Profile from Variational AI

Indeterminate GlobeNewswire

8 hours ago

Nxera Pharma Enters into Exclusive License, Supply and Commercialization Agreement with Synmosa for QUVIVIQ® (daridorexant) Across Eight Asia-Pacific Markets

Indeterminate GlobeNewswire

10 hours ago

Pharming presents positive Phase II topline data for leniolisib in genetic PIDs with immune dysregulation at ESID 2026

Indeterminate GlobeNewswire